Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000134.xml
Diabetologie und Stoffwechsel 2022; 17(06): 462-471
DOI: 10.1055/a-1837-2035
DOI: 10.1055/a-1837-2035
Übersicht
Krebsrisiko bei Prädiabetes und Typ-2-Diabetes mellitus
Prediabetes or type-2-diabetes and cancer risk
Zusammenfassung
Krebs ist nun die führende Todesursache bei Typ-2-Diabetes mellitus (T2D). Prädiabetes und T2D erhöhen das Risiko für bestimmte Tumoren. Zu den Prädiabetes- bzw. T2D-assoziierten Malignomen zählen gastrointestinale, gynäkologische, urologische und endokrine Karzinome aber auch Leukämien. Prädiabetes und T2D bedingen eine 1,2- bis 2,7-fach erhöhte Krebssterblichkeit. Zugrundeliegende Mechanismen der Assoziation zwischen T2D und Krebs beinhalten die chronische Hyperglykämie, einen chronischen systemischen Entzündungszustand, oxidativen Stress, Dyslipidämie, die Insulinresistenz sowie chronisch erhöhte Spiegel von insulin-like growth factor 1 (IGF-1) und von Insulin. Eine dauerhafte Gewichtsreduktion kann das Krebsrisiko adipöser T2D-Patienten signifikant senken. Ein gesunder Lebensstil und die regelmäßige Teilnahme an Vorsorgeuntersuchungen sind wichtig und können die Krebsmortalität von Diabetespatienten erheblich verringern.
Abstract
Cancer has become the leading cause of death among patients with type-2-diabetes (T2D). Both prediabetes and T2D increase cancer risk. Prediabetes and T2D are causally associated with gastrointestinal, gynecologic, urologic and endocrine cancers as well as leukemias. Both prediabetes and T2D raise cancer mortality by 1.2- to 2.7-fold. Mechanisms underlying the association between T2D and cancer are chronic hyperglycemia, chronic systemic inflammation, oxidative stress, dyslipidemia, insulin resistance and chronic high levels of insulin and insulin-like growth factor 1 (IGF-1). Intentional long-term weight loss reduces the cancer risk of obese T2D-patients. Both a healthy lifestyle and cancer screening are effective and can decrease cancer mortality among T2D-patients.
Publication History
Received: 17 February 2022
Accepted after revision: 26 April 2022
Article published online:
01 June 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol 2021; 9: 165-173
- 2 Collier A, Meney C, Hair M. et al. Cancer has overtaken cardiovascular disease as the commonest cause of death in Scottish type 2 diabetes patients: A population-based study (The Ayrshire Diabetes Follow-up Cohort study). J Diabetes Investig 2020; 11: 55-61
- 3 Nakamura J, Kamiya H, Haneda M. et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 2017; 8: 397-410
- 4 Saydah SH, Loria CM, Eberhardt MS. et al. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol 2003; 157: 1092-1100
- 5 Zhou XH, Qiao Q, Zethelius B. et al. DECODE Study Group. Diabetes, prediabetes and cancer mortality. Diabetologia 2010; 53: 1867-1876
- 6 Huang Y, Cai X, Qiu M. et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia 2014; 57: 2261-2269
- 7 Tsilidis KK, Kasimis JC, Lopez DS. et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 2015; 350: g7607
- 8 Chen Y, Wu F, Saito E. et al. Association between type 2 diabetes and risk of cancer mortality: a pooled analysis of over 771,000 individuals in the Asia Cohort Consortium. Diabetologia 2017; 60: 1022-1032
- 9 Saarela K, Tuomilehto J, Sund R. et al. Cancer incidence among Finnish people with type 2 diabetes during 1989–2014. Eur J Epidemiol 2019; 34: 259-265
- 10 Ling S, Brown K, Miksza JK. et al. Association of Type 2 Diabetes With Cancer: A Meta-analysis With Bias Analysis for Unmeasured Confounding in 151 Cohorts Comprising 32 Million People. Diabetes Care 2020; 43: 2313-2322
- 11 Bjornsdottir HH, Rawshani A., Rawshani A.. et al. A national observation study of cancer incidence and mortality risks in type 2 diabetes compared to the background population over time. Sci Rep 2020; 10: 17376
- 12 Ke J, Lin T, Liu X. et al. Glucose Intolerance and Cancer Risk: A Community-Based Prospective Cohort Study in Shanghai, China. Front Oncol 2021; 11: 726672
- 13 Boursi B, Finkelman B, Giantonio BJ. et al. A Clinical Prediction Model to Assess Risk for Pancreatic Cancer Among Patients With Prediabetes. Eur J Gastroenterol Hepatol 2022; 34: 33-38
- 14 Hirakawa Y, Ninomiya T, Mukai N. et al. Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama Study. Am J Epidemiol 2012; 176: 856-64
- 15 Islam Z, Akter S, Inoue Y. et al. Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study. Diabetes Care 2021; 44: 757-764
- 16 Dagenais GR, Leong DP, Rangarajan S. et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785-794
- 17 Sung H, Siegel RL, Rosenberg PS. et al. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4: e137-e147
- 18 Ali Khan U, Fallah M, Sundquist K. et al. Risk of colorectal cancer in patients with diabetes mellitus: A Swedish nationwide cohort study. PLoS Med 2020; 17 (11) e1003431
- 19 Lu S, Wang A, Miao S. et al. Association between type 2 diabetes and cancer incidence in China: data in hospitalized patients from 2006 to 2013. Ann Transl Med 2020; 8: 176
- 20 Li Z, Chen H, Fritz CD. et al. Type 2 Diabetes and Risk of Early-Onset Colorectal Cancer. medRxiv 2021;
- 21 Mikaeel RR, Symonds EL, Kimber J. et al. Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pac J Clin Oncol 2021; 17: 131-138
- 22 Wang YG, Wang P, Wang B. et al. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS One 2014; 9 (05) e95485
- 23 Mao Y, Tao M, Jia X. et al. Effect of Diabetes Mellitus on Survival in Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Sci Rep 2015; 5: 17102
- 24 Sheng L, Peng H, Pan Y. et al. Evaluating the effect of diabetes on the prognosis of gastric cancer using a propensity score matching method. J Gastrointest Oncol 2020; 11 (05) 999-1008
- 25 Petrelli F, Ghidini M, Rausa E. et al. Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. Can J Diabetes 2021; 45 (02) 186-197.e2
- 26 Suh S, Kim KW. Diabetes and Cancer: Cancer Should Be Screened in Routine Diabetes Assessment. Diabetes Metab J 2019; 43 (06) 733-743
- 27 Zhu B, Qu S. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol 2022; 13: 800995
- 28 von Wagner C, Cadar D, Hackett RA. et al. Type 2 diabetes and colorectal cancer screening: Findings from the English Longitudinal Study of Ageing. J Med Screen 2020; 27: 25-30
- 29 Bhatia D, Lega IC, Wu W. et al. Breast, cervical and colorectal cancer screening in adults with diabetes: a systematic review and meta-analysis. Diabetologia 2020; 63: 34-48
- 30 Chuck KW, Hwang M, Choi KS. et al. Cancer screening rate in people with diabetes in the Korean population: results from the Korea National Health and Nutrition Examination Survey 2007–2009. Epidemiol Health 2017; 39: e2017036
- 31 Valent F, Gobbato M, Franzo A. et al. Diabetes mellitus and colorectal cancer screening in the population of the Italian region Friuli Venezia Giulia. Epidem Biostati Public Health 2017; 14
- 32 Schell D, Ullah S, Brooke-Smith ME. et al. Gastrointestinal Adenocarcinoma Incidence and Survival Trends in South Australia, 1990–2017. Cancers (Basel) 2022; 14: 275
- 33 Sjöholm K, Carlsson LMS, Svensson PA. et al. Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-Term Results From the Swedish Obese Subjects Study. Diabetes Care 2022; 45 (02) 444-450
- 34 Mao D, Lau ESH, Wu H. et al. Risk associations of long-term HbA1c variability and obesity on cancer events and cancer-specific death in 15,286 patients with diabetes – A prospective cohort study. Lancet Reg Health West Pac 2021; 18: 100315
- 35 Zhang K, Bai P, Dai H. et al. Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Prim Care Diabetes 2021; 15: 52-58
- 36 Cunha V, Cotrim HP, Rocha R. et al. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review. Ann Hepatol 2020; 19 (03) 232-237
- 37 Wang J, Kim CH. Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases. Endocr Res 2022; 47 (01) 18-25
- 38 Gallagher EJ, LeRoith D. Hyperinsulinaemia in cancer. Nat Rev Cancer 2020; 20: 629-644
- 39 Li W, Zhang X, Sang H. et al. Effects of hyperglycemia on the progression of tumor diseases. J Exp Clin Cancer Res 2019; 38: 32
- 40 https://www.nfcr.org/blog/understanding-the-link-between-sugar-and-cancer-2021/
- 41 Lee SC, Chan JC. Evidence for DNA damage as a biological link between diabetes and cancer. Chin Med J (Engl) 2015; 128: 1543-1548
- 42 Cardoso R, Zhu A, Guo F. et al. Inzidenz und Mortalität proximaler und distaler kolorektaler Karzinome in Deutschland – Trends in der Ära der Vorsorgekoloskopie. Dtsch Arztebl Int 2021; 118: 281-287
- 43 Patel SG, Karlitz JJ, Yen T. et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection. Lancet Gastroenterol Hepatol 2022;
- 44 Vuik F, Nieuwenburg S, Bardou M. et al. Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. Gut 2019; 68: 1820-1826
- 45 Restifo D, Williams JS, Garacci E. et al. Differential relationship between colorectal cancer and diabetes in a nationally representative sample of adults. J Diabetes Complications 2018; 32: 819-823
- 46 Xu J, Ye Y, Wu H. et al. Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open 2016; 6: e011430
- 47 Tran TT, Gunathilake M, Lee J. et al. Association between metabolic syndrome and its components and incident colorectal cancer in a prospective cohort study. Cancer 2022; 128 (06) 1230-1241
- 48 Davidson KW, Barry MJ, Mangione CM. US Preventive Services Task Force. et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 325 (19) 1965-1977
- 49 Li H, Boakye D, Chen X. et al. Associations of body mass index at different ages with early-onset colorectal cancer. Gastroenterology 2022; 162: 1088-1097.e3
- 50 Flemming JA, Djerboua M, Groome PA. et al. NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. Hepatology 2021; 74 (06) 3330-3344
- 51 Han H, Zhang T, Jin Z. et al. Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies. Oncotarget 2017; 8 (30) 50164-50173
- 52 Banal KA, Paz-Pacheco E, de Villa V. Diabetes Mellitus and Prediabetes in Patients with Hepatocellular Carcinoma in a Tertiary Philippine Hospital. J ASEAN Fed Endocr Soc 2017; 32 (01) 32-37
- 53 Baecker A, Liu X, La Vecchia C. et al. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 2018; 27: 205-212
- 54 Chen CL, Yang HI, Yang WS. et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135 (01) 111-21
- 55 Simon TG, King LY, Chong DQ. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67: 1797-1806
- 56 Luo X, Sui J, Yang W. et al. Type 2 Diabetes Prevention Diet and Hepatocellular Carcinoma Risk in US Men and Women. Am J Gastroenterol 2019; 114: 1870-1877
- 57 Rustgi VK, Li Y, Gupta K. et al. Bariatric Surgery Reduces Cancer Risk in Adults With Nonalcoholic Fatty Liver Disease and Severe Obesity. Gastroenterology 2021; 161 (01) 171-184.e10
- 58 Park JH, Hong JY, Park YS. et al. Association of prediabetes, diabetes, and diabetes duration with biliary tract cancer risk: A nationwide cohort study. Metabolism 2021; 123: 154848
- 59 Petrick JL, Thistle JE, Zeleniuch-Jacquotte A. et al. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. Am J Gastroenterol 2018; 113: 1494-1505
- 60 Lai HC, Chang SN, Lin CC. et al. Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. J Gastroenterol 2013; 48: 856-865
- 61 Gu J, Yan S, Wang B. et al. Type 2 diabetes mellitus and risk of gallbladder cancer: a systematic review and meta-analysis of observational studies. Diabetes Metab Res Rev 2016; 32: 63-72
- 62 Lee BS, Park EC, Park SW. et al. Hepatitis B virus infection, diabetes mellitus, and their synergism for cholangiocarcinoma development: a case-control study in Korea. World J Gastroenterol 2015; 21 (02) 502-510
- 63 Salinas-Martínez AM, Flores-Cortés LI, Cardona-Chavarría JM. et al. Prediabetes, diabetes, and risk of breast cancer: a case-control study. Arch Med Res 2014; 45 (05) 432-438
- 64 Schrijnders D, Hendriks SH, Kleefstra N. et al. Sex differences in obesity related cancer incidence in relation to type 2 diabetes diagnosis (ZODIAC-49). PLoS One 2018; 13: e0190870
- 65 Boyle P, Boniol M, Koechlin A. et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer 2012; 107: 1608-1617
- 66 Chen X, Wang Q, Zhang Y. et al. Physical Activity and Risk of Breast Cancer: A Meta-Analysis of 38 Cohort Studies in 45 Study Reports. Value Health 2019; 22: 104-128
- 67 Luo J, Hendryx M, Manson JE. et al. Intentional Weight Loss and Obesity-Related Cancer Risk. JNCI Cancer Spectr 2019; 30 (04) kz054
- 68 Graff RE, Sanchez A, Tobias DK. et al. Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. Diabetes Care 2018; 41: 1432-1437
- 69 Wang S, Lo Galbo MD, Blair C. et al. Diabetes and kidney cancer risk among post-menopausal women: The Iowa womenʼs health study. Maturitas 2021; 143: 190-196
- 70 Blackford AL, Canto MI, Klein AP. et al. Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. J Natl Cancer Inst 2020; 112 (11) 1162-1169
- 71 Khadka R, Tian W, Hao X. et al. Risk factor, early diagnosis and overall survival on outcome of association between pancreatic cancer and diabetes mellitus: Changes and advances, a review. Int J Surg 2018; 52: 342-346
- 72 GBD 2017 Pancreatic Cancer Colla borators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990- 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2019; 4: 934-947
- 73 Ose DJ, Viskochil R, Holowatyj AN. et al. Understanding the Prevalence of Prediabetes and Diabetes in Patients With Cancer in Clinical Practice: A Real-World Cohort Study. J Natl Compr Canc Netw 2021; 19 (06) 709-718
- 74 Yuan C, Babic A, Khalaf N. et al. Diabetes, Weight Change, and Pancreatic Cancer Risk. JAMA Oncol 2020; 6 (10) e202948
- 75 Duconseil P, Adham M, Sauvanet A. et al. Fukuoka-Negative Branch-Duct IPMNs: When to Worry? A Study from the French Surgical Association (AFC). Ann Surg Oncol 2018; 25: 1017-1025
- 76 Scherübl H. Übermäßiges Körpergewicht und Krebsrisiko. Dtsch Med Wochenschr 2020; 145 (14) 1006-1014
- 77 Xu B, Zhou X, Li X. et al. Diabetes mellitus carries a risk of esophageal cancer: A meta-analysis. Medicine (Baltimore) 2017; 96 (35) e7944
- 78 Petrick JL, Li N, Anderson LA. et al. Diabetes in relation to Barrett's esophagus and adenocarcinomas of the esophagus: A pooled study from the International Barrett's and Esophageal Adenocarcinoma Consortium. Cancer 2019; 125 (23) 4210-4223
- 79 Bergquist JR, Leiting JL, Habermann EB. et al. Early-onset gastric cancer is a distinct disease with worrisome trends and oncogenic features. Surgery 2019; 166: 547-555
- 80 Jun JK, Choi KS, Lee HY. et al. Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality. Gastroenterology 2017; 152: 1319-1328
- 81 Wu Y, Li Y, Giovannucci E. Potential Impact of Time Trend of Lifestyle Risk Factors on Burden of Major Gastrointestinal Cancers in China. Gastroenterology 2021; 161 (06) 1830-1841.e8
- 82 https://www.euro.who.int/en/countries/ireland/news2/news/2021/5/ireland-leads-the-way-on-tobacco-cessation-programmes
- 83 Starker A, Buttmann-Schweiger N, Krause L. et al. Krebsfrüherkennungsuntersuchungen in Deutschland: Angebot und Inanspruchnahme. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018; 61: 1491-1499